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Regulation of Connective Tissue Growth Factor Activity in
Cultured Rat Mesangial Cells and Its Expression in
Experimental Diabetic Glomerulosclerosis
BRUCE L. RISER,* MARK DENICHILO,† PEDRO CORTES,* CATHRYN BAKER,†
JANET M. GRONDIN,* JERRY YEE,* and ROBERT G. NARINS*
*Department of Internal Medicine, Division of Nephrology, Henry Ford Hospital, Detroit, Michigan; and
†
FibroGen, South San Francisco, California.

Abstract. Connective tissue growth factor (CTGF) is a peptide
secreted by cultured endothelial cells and fibroblasts when
stimulated by transforming growth factor-␤ (TGF-␤), and is
overexpressed during fibrotic processes in coronary arteries
and in skin. To determine whether CTGF is implicated in the
pathogenesis of diabetic glomerulosclerosis, cultured rat mesangial cells (MC) as well as kidney cortex and microdissected
glomeruli were examined from obese, diabetic db/db mice and
their normal counterparts. Exposure of MC to recombinant
human CTGF significantly increased fibronectin and collagen
type I production. Furthermore, unstimulated MC expressed
low levels of CTGF message and secreted minimal amounts of
CTGF protein (36 to 38 kD) into the media. However, sodium
heparin treatment resulted in a greater than fourfold increase in
media-associated CTGF, suggesting that the majority of CTGF
produced was cell- or matrix-bound. Exposure of MC to
TGF-␤, increased glucose concentrations, or cyclic mechanical
strain, all causal factors in diabetic glomerulosclerosis, markedly induced the expression of CTGF transcripts, while recombinant human CTGF was able to autoinduce its own expres-

sion. TGF-␤ and high glucose, but not mechanical strain,
stimulated the concomitant secretion of CTGF protein, the
former also inducing abundant quantities of a small molecular
weight form of CTGF (18 kD) containing the heparin-binding
domain. The induction of CTGF protein by a high glucose
concentration was mediated by TGF-␤, since a TGF-␤-neutralizing antibody blocked this stimulation. In vivo studies using
quantitative reverse transcription-PCR demonstrated that although CTGF transcripts were low in the glomeruli of control
mice, expression was increased 28-fold after approximately 3.5
mo of diabetes. This change occurred early in the course of
diabetic nephropathy when mesangial expansion was mild, and
interstitial disease and proteinuria were absent. A substantially
reduced elevation of CTGF mRNA (twofold) observed in
whole kidney cortices indicated that the primary alteration of
CTGF expression was in the glomerulus. These results suggest
that CTGF upregulation is an important factor in the pathogenesis of mesangial matrix accumulation and progressive
glomerulosclerosis, acting downstream of TGF-␤.

Acute imbalances in the expression, distribution, and/or biologic activities of cytokines such as transforming growth factor-␤ (TGF-␤) and platelet-derived growth factor (PDGF) are
an important part of the initial response to renal injury and are
necessary for the increased collagen formation that is part of
normal wound healing (1,2). However, a sustained imbalance
in these factors may lead to progressive renal sclerosis with
eventual organ failure. The evidence for such an effect appears
strongest for TGF-␤. The exposure of either cultured mesangial cells (MC) or glomeruli to this cytokine results in in-

creased extracellular matrix (ECM) production (3,4), mirroring
the overaccumulation of mesangial matrix components that
characterizes the lesion in vivo (5). Furthermore, TGF-␤ activity is increased in a variety of both human and experimental
forms of glomerulosclerosis (6 – 8), and ECM production is
induced after the transfection and overexpression of the TGF-␤
gene in the rat kidney (9). Finally, treatment with anti-TGF-␤
antibody attenuates the enhanced glomerular ECM gene expression that occurs in experimental glomerulonephritis (10)
and in experimental diabetic glomerulosclerosis (11).
Two factors that appear responsible for the sustained overexpression of TGF-␤ are a high extracellular glucose concentration and altered glomerular hemodynamics. Exposure of MC
to increased glucose concentrations stimulates the production
and binding of TGF-␤1 (12–14) in concert with induction of
ECM production (15,16). The stimulation of TGF-␤1 production is attributed, at least in part, to transcriptional activation
involving a region in the TGF-␤1 promoter containing a glucose-response element (17). The mechanisms for the hemodynamically induced TGF-␤ activity are also becoming apparent.
In diabetes and in the remnant kidney, the impairment of
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glomerular pressure autoregulation (18) results in the exposure
of the capillary bed to the large moment-to-moment variations
in systemic BP (19). Due to the elasticity of the glomerulus,
this increased capillary pressure produces expansion of the
structure and MC mechanical strain (20). The consequence of
this mechanical stimulation is increased production, release,
activation, and binding of TGF-␤1, as shown in cultured MC
subjected to cyclic stretching (14,21). This same treatment also
results in increased synthesis and accumulation of mesangial
matrix components, fibronectin, laminin, and collagen types I
and IV (20). Furthermore, the marked induction of MC collagen synthesis by high glucose levels, or the combined effects
of high glucose and cyclic stretching are significantly reduced
by neutralization of TGF-␤ (13,22).
A cytokine that may act downstream of TGF-␤ to regulate
matrix metabolism is connective tissue growth factor (CTGF).
Human CTGF (hCTGF) was first identified as a product of
human umbilical vein endothelial cells that was chemotactic
and mitogenic for fibroblasts (23). It is now known to be one
of the seven cysteine-rich secreted proteins that comprise the
CTGF family (24). These related proteins are comprised of
four modules and one signal peptide (24). The four modules
include an insulin-like growth factor-binding domain, a von
Willebrand factor type C repeat likely involved in oligomerization, a thrombospondin type 1 repeat thought to be involved
in binding to the ECM, and a C-terminal module that may be
involved in receptor binding. The human, mouse, and rat
CTGF are highly conserved proteins with greater than 90%
amino acid homology and a molecular mass of approximately
37 kD (24).
The biologic activities of CTGF have been incompletely
studied. However, in the aggregate, an important emerging role
for CTGF is that of a prosclerotic mediator in both dermal
fibrosis and coronary atherosclerosis. Recombinant human
CTGF (rhCTGF) injected under the skin of mice induces the
same rapid and dramatic increases of connective tissue cells
and ECM as occur with a similar treatment with TGF-␤;
however, PDGF and epidermal growth factor (EGF) have little
or no such effect (25). CTGF mRNA is expressed by fibroblasts in the lesions of patients with progressive systemic
sclerosis, keloids, and localized scleroderma, while there is no
expression in adjacent normal skin (26). Furthermore, CTGF
may mediate, at least in part, the fibrogenic properties of
TGF-␤. For example, cultured normal human skin fibroblasts
respond to TGF-␤ by increasing CTGF mRNA and protein but
do not respond in a similar manner to PDGF, EGF, or basic
fibroblast growth factor (bFGF) (27). The mechanism of this
specificity for cytokines in these cells has been demonstrated
with the identification of a novel TGF-␤ responsive element in
the CTGF promoter (28). Moreover, fibroblasts from lesions of
scleroderma display increased mitogenesis to TGF-␤ and produce greater amounts of CTGF than normal fibroblasts (29). In
addition, cultured vascular smooth muscle cells are also stimulated by TGF-␤ to produce CTGF, and in coronary disease,
CTGF mRNA is expressed 50- to 100-fold higher in atherosclerotic plaques than in the normal arterial wall (30).
Although CTGF is causally implicated in dermal fibrosis
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and atherosclerosis via its apparent stimulation by TGF-␤, very
little is known about the level and control of its expression
during the development of glomerulosclerosis. Recently, kidney biopsy specimens from patients with various forms of renal
disease were examined for CTGF mRNA by in situ hybridization and compared to areas of normal tissue in kidneys with
localized renal tumors (31). A qualitative assessment indicated
that compared to the normal tissue, glomerular CTGF message
appeared as upregulated in lesions of crescentic glomerulonephritis, IgA nephropathy, focal and segmental glomerulosclerosis, and diabetic nephropathy. Based on the above evidence,
we hypothesized that CTGF may be an important mediator of
ECM accumulation in diabetic glomerulosclerosis. To test this
theory, we studied the expression and matrix-inducing effects
of CTGF in cultured MC. In addition, we examined glomerular
and whole renal CTGF activity in experimental diabetes and its
relationship to the level of mRNA expression for ECM components and the degree of mesangial expansion and proteinuria.

Materials and Methods
Cells and Tissue Culture
The MC, previously characterized and described by us, were a
cloned line derived from outgrowths of Fischer rat glomeruli (13).
Upon serial passage, they continue to express key markers of MC
(13). The medium used was RPMI 1640 with penicillin and streptomycin and, unless otherwise noted, 5 mM glucose. MC growth medium contained 20% Nu-serum from Collaborative Research
(Bedford, MA). Unless otherwise noted, MC were cultured for approximately 4 d in growth medium and, when reaching confluence,
were washed twice with serum-free medium and incubated for 24 to
48 h under serum-deprived (0.5% fetal calf serum [FCS]) conditions.
The cultures were then incubated for a designated period in fresh
maintenance medium (0.5% FCS), with or without experimental treatments. At the concentration of FCS used in these studies, there was no
active TGF-␤1, -2, or -3 detectable in the fresh medium, as determined by a highly sensitive mink lung bioassay (our unpublished
observation). The renal fibroblasts used in Northern analysis were
mouse tubulointerstitial fibroblasts, as described by Alvarez et al.
(32).
Experiments testing the effects of mechanical strain were carried
out as described previously (13). In brief, MC were seeded into
6-well, Flex I plates (5 ⫻ 104 cells/25-mm diameter well) with
flexible collagen-coated bottoms from Flexcell International (McKeesport, PA) and cultured in 1 ml/well of growth medium. After
24 h, experimental cultures were subjected to cyclic stretching while
the control cultures were maintained in a static environment under
identical conditions. In an attempt to mimic conditions of MC stretch
during possible low frequency oscillations in intraglomerular pressure, all experiments were carried out using alternating cycles of 10-s
stretch and 10-s relaxation (50 mHz) (33). Vacuum intensity was set
to provide an average elongation of approximately 8% over the entire
culture surface (34).

Animals and Specimen Collection
Diabetic male db/db mice and their nondiabetic db/m littermates
were from Jackson Laboratories (Bar Harbor, ME). The db/db mouse
carries a defective receptor gene for leptin, a key weight control
hormone (35). These mice become obese at 3 to 4 wk of age and
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develop hyperglycemia. Associated nephropathy includes proteinuria
and mesangial expansion with increased mesangial matrix that develops by 5 to 7 mo (36). In the present experiments, mice were
sacrificed at the age of 5 mo, when incipient glomerular lesions were
expected to occur. Blood glucose levels were determined during the
study and at sacrifice, using a colorimetric method based on the
glucose oxidase-peroxidase reaction and supplied in a kit form (Glucose Procedure No. 510 kit) from Sigma Diagnostics (St. Louis, MO).
After 24-h acclimation to metabolic cages, two consecutive 24-h urine
samples were collected. At the end of the collection period, the lower
part of the cage including the collection funnel was rinsed with
distilled water and the final sample volume was recorded. Protein
concentration in the urine was measured according to the method of
Bradford (37).
After anesthesia by an oxygen/ether mixture, the abdominal cavity
was opened, a 23-gauge needle was inserted into the aorta, and the
kidneys were perfused with 4 ml of ice-cold perfusion buffer (RPMI
with 4% bovine serum albumin [BSA]) containing 10 mM vanadyl
ribonucleoside complex, an RNase inhibitor from Life Technologies/
BRL (Grand Island, NY). Chilled 0.9% saline was poured over the
kidneys during this perfusion. The kidneys were then removed and the
right kidney was frozen in liquid nitrogen for subsequent RNA extraction and Northern analysis. Fine sagittal slices of the left kidney
were rapidly obtained. One section was fixed in 3.8% paraformaldehyde, embedded in paraffin, and stained with periodic-acid Schiff
(PAS) for light microscopic evaluation. The remaining slices were
used for glomerular microdissection and reverse transcription (RT)PCR of the isolated glomeruli. The methods used were a modification
of those described previously by Peten et al. for determination of
glomerular mRNA levels (38). In brief, tissue sections were placed in
a buffer of Hanks’ balanced salt solution containing 10 mM vanadyl
ribonucleoside complex, then 50 glomeruli were dissected from each
kidney in less than 50 min. The glomeruli were next transferred to a
PCR tube with 30 l of rinse buffer (Hanks’ balanced salt solution
containing 5 mM dithiothreitol and 50 U/ml human placental ribonuclease inhibitor from Boehringer Mannheim [Indianapolis, IN]). After
centrifugation, the supernatant was removed and microscopically examined for the accidental presence of glomeruli. Seven microliters of
a lysis solution (rinse buffer containing 2% Triton X-100) was added,
and the samples were stored at ⫺70°C until processed. All of these
procedures were carried out at 4°C.
Experimental samples from control and diabetic mice were thawed
on ice, then subjected to two additional freeze/thaw cycles to lyse the
glomeruli. The RT reaction was then carried out using a cDNA
synthesis kit from Boehringer Mannheim, with oligo(dT) as a primer.
Reactions containing glomeruli, but without added reverse transcriptase, or without glomeruli, but with reverse transcriptase, served as
negative controls. The reaction mixture was incubated for 60 min at
42°C, then chilled to 4°C for 10 min. Samples were then diluted 1:10
in distilled water and frozen at ⫺70°C until PCR was done.

Evaluation of Renal Tissue by Light Microscopy
Five to six nonconsecutive 6-m sections per kidney were PASstained and examined. Mesangial sclerosis was scored on a scale of 0
to 4. (0, no lesion; 1, minimal mesangial expansion; 2, mesangial
expansion and/or basement membrane thickening; 3, marked mesangial thickening, some collapsed lumina, occasional lobule with full
sclerosis; 4, diffuse collapse of capillary lumina and sclerosis involving 75% or more of the tuft). A total of 100 to 150 glomeruli per
kidney was scored by an observer blinded to the origin of the specimens. Only glomerular profiles showing a mesangial region that could
be unequivocally evaluated were scored.
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Competitive PCR and Northern Blotting
All PCR was performed using the GeneAmp DNA amplification
kit from Perkin-Elmer-Cetus (Norwalk, CT) and a Perkin-Elmer 9600
thermal cycler. For quantification, a competitive PCR reaction was
run using a c-DNA mimic. Thirty-eight cycles of replication were
used. Five PCR tubes were set up for each sample. Each tube in a
series contained a fixed amount of the wild-type cDNA along with
decreasing concentrations of the mimic cDNA. The products were
separated by agarose gel electrophoresis and visualized by ethidium
bromide staining. Bands were digitized by scanning densitometry
using a Howtek, Scanmaster 3⫹ Densitometer (Hudson, NH) and
quantified with image analysis using NIH Image, version 1.59, from
Twilight Clone BBS (Silver Spring, MD). A plot of the ratio of
wild-type/mimic versus the reciprocal of the input mutant concentration was constructed, and the amount of glomerular cDNA was
determined from the resulting linear regression. Northern analysis was
carried out as described previously (21), following pulverization of
samples in a liquid nitrogen cooled stainless-steel mortar and homogenization in 1.0 ml of RNA Stat-60 reagent from Tel-Test, Inc.
(Friendswood, TX). Probes for individual mRNA, the corresponding
cDNA, were labeled with 32P by random hexamer priming using the
Sigma Prime-1 kit from Sigma Chemical. Autoradiograms were digitized by scanning densitometry and quantified as above.

Primers, Probes, and cDNA Mimics
Primers for CTGF were designed and synthesized based on conserved sequences between the human and mouse CTGF (fisp 12)
gene. They were F: 5⬘-GAG TGG GTG TGT GAC GAG CCC AA G
G-3⬘ and R: 5⬘-ATG TCT CCG TAC ATC TTC CTG TAG T-3⬘. The
amplification product was 558 bp in size. The sequence was confirmed by cloning into pCR script from Invitrogen (Carlsbad, CA).
Two clones were sequenced and were identical. A competitive cDNA
mimic was produced using a PCR mimic construction kit (K1700-1)
from Clontech Laboratories (Palo Alto, CA). For each mimic, two
composite primers (3⬘ and 5⬘) were first made containing the target
gene sequence (CTGF) plus a 20-nucleotide stretch designed to hybridize to opposite strands of a heterologous DNA fragment provided
in the kit. The desired primer sequences were then incorporated into
this fragment during a PCR amplification. A dilution of the first PCR
reaction was then amplified using only the gene-specific primers,
ensuring that all mimic molecules had complete gene-specific sequences. The mimic was then purified by passage through CHROMA
SPIN TE-100 columns from Clontech. By this method, the size (200
to 650 bp) could be adjusted by choosing the appropriate sequences of
the generic DNA fragment for the composite primers. The resulting
cDNA competes on an equal basis for the same primers in the same
reaction. Amplimer of the CTGF mimic was 496 bp in size.
Primers for rat fibronectin cDNA were F: 5⬘-TGC CAC TGT TCT
CCT ACG TG-3⬘ and R: 5⬘-ATG CTT TGA CCC TTA CAC GG-3⬘.
A competitive mimic for fibronectin was constructed as described
above. Products of amplification were approximately 312 (sample)
and 474 bp (mimic). Primers for GAPDH were obtained from Clontech and produced an amplification fragment of 985 bp. A GAPDH
competitive mimic was constructed as described above, and produced
a fragment of 604 bp. The cDNA probe for Northern analysis was
from a sequence of human CTGF shared by rat and mouse. The cDNA
probe for TGF-␤1 (pRTGF␤1) was a gift from Drs. Su Wen Qian and
Anita Roberts at the National Cancer Institute (Bethesda, MD). The
fibronectin cDNA probe (39) was a gift from Dr. Subhas Chakrabarty
at The University of Texas.
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Production of Recombinant CTGF and
anti-CTGF Antibodies
Recombinant human CTGF protein (rhCTGF) was generated using
a baculoviral expression system. In brief, the human CTGF openreading frame (1047 bp) was amplified using primers engineered with
BamHI sites immediately flanking the ATG start codon and TGA stop
codon (forward primer 5⬘-GCT CCG CCC GCA GTG GGA TCC
ATG ACC GCC GCC-3⬘; reverse primer 5⬘-GGA TCC GGA TCC
TCA TGC CAT GTC TCC GTA-3⬘). Clone DB60R32 was used as
template (23), which contains the entire 2075-bp CTGF cDNA. The
amplified product was subcloned into the BamHI site of pFastBac1
from Life Technologies/BRL, analyzed for insert orientation, and
verified by sequencing of both DNA strands. Generation of recombinant baculovirus containing the CTGF cDNA was performed as
outlined by Life Technologies/BRL (pFastBac expression system).
Recombinant baculovirus stocks were isolated, expanded to high virus
titer, and used to infect High Five insect cells (Invitrogen, Carlsbad,
CA) for expression of CTGF. The recombinant CTGF was purified by
heparin-Sepharose affinity chromatography as described previously
(25). Peak fractions containing rhCTGF were determined by immunoblotting and Coomassie staining of sodium dodecyl sulfate (SDS)polyacrylamide gels (25).
Two anti-CTGF antibodies were used. The first, anti-CTGF polyclonal pAb839, was prepared through a contract service with Quality
Controlled Biochemicals (Hopkinton, MA) by immunizing rabbits
with a keyhole limpet hemocyanin-coupled synthetic peptide corresponding to amino acids 329 to 343 (CPG DND IFE SLY YRK) that
is unique to the carboxy terminus of CTGF. The production of
antibody was monitored by enzyme-linked immunosorbent assay
(ELISA) with the peptide conjugated to BSA and absorbed to plastic.
The anti-CTGF antibodies were affinity-purified by passage through a
CPG DND IFE SLY YRK-Sepharose peptide column using standard
protocols (40). Peptide-blocking studies confirmed the monospecificity of pAb839 for CTGF in Western immunoblotting assays. Western
immunoblot analysis also revealed that pAb839 recognized CTGF
only in a reduced conformation. The second antibody, pIgY3 polyclonal, was raised in chickens by immunizing with purified baculovirus-derived full-length rhCTGF protein as described previously (41),
and was subsequently affinity-purified through a rhCTGF-Sepharose
column.

ELISA
The amount of specific ECM components secreted into the culture
medium was quantified by ELISA, using a described procedure (20).
It was previously determined in MC cultures that media containing 0.5
to 1% FCS was optimal for the recovery of fibronectin and collagen
(20). Experimental samples of culture medium were tested in triplicate. Purified matrix components, diluted in the same medium, were
run (0.5 to 500 ng/well) as standards. All antisera were tested for
specificity before their use by immunoblotting, with and without
blocking, using the ECM standards. Color intensity was measured
with a Titertek Multiscan MCC/340 from Flow Laboratories
(McLean, VA), and the results were analyzed using a curve-fitter
computer program from Interactive Microware (State College, PA).
An indirect ELISA was used to quantify CTGF levels in the
conditioned media. In brief, microtiter wells were coated with media
samples or the rhCTGF standard (50 l/well) for 2 h at room temperature in a 96-well plate. The wells were washed 4 times with
Dulbecco’s phosphate-buffered saline (D-PBS) and then incubated
with pIgY3 antibody at 1.25 g/ml (50 l/well) in blocking buffer
(1% BSA, 0.05% Tween 20 in D-PBS) for 60 min. After thorough
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washing with D-PBS, a horseradish peroxidase (HRP)-conjugated
rabbit anti-chicken IgG from Zymed Laboratories (South San Francisco, CA) was added to all wells at a 1:6400 dilution in blocking
buffer for 30 min. The substrate, TMB-ELISA from Life Technologies/BRL, was added at room temperature for 15 min, the reaction
was stopped with 1 M sulfuric acid, and the color developed was read
at 450 nm in an ELISA multiscan spectrophotometer (Molecular
Dynamics, Sunnyvale, CA). The amount of CTGF protein present in
samples was determined using a logarithmic standard curve with
serial dilutions (3 pg to 3 ng/well) of rhCTGF standard antigen.

Heparin-Sepharose Precipitation and Immunoblotting
To analyze for CTGF protein expression, conditioned media were
collected and the heparin-binding proteins were precipitated by endover-end mixing for 4 h at 4°C with heparin-Sepharose CL-6B beads
from Pharmacia (Piscataway, NJ). The beads were washed three times
with ice-cold radioimmunoprecipitation assay lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 1% deoxycholate,
0.1% SDS, and 2 mM ethylenediaminetetra-acetic acid). The bound
proteins were then eluted by boiling in SDS sample buffer (62 mM
Tris-HCl, pH 6.8, 2.3% SDS, 10% glycerol and bromphenol blue) for
5 min under either nonreducing or reducing conditions (containing 5%
mercaptoethanol). The eluted heparin-binding proteins were resolved
in 4 to 20% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose filters from Schleicher & Schuell (Keene, NH)
for 2 h at 140 mA. The filters were blocked with blocking buffer
(TTBS; 150 mM NaCl, 50 mM Tris, 0.2% Tween 20, 5% BSA, pH
7.4) for 2 h at room temperature and then probed for CTGF by
incubation for 40 min with anti-CTGF antibody at 0.5 g/ml in
blocking buffer. After extensive washing at 37°C, the filters were
incubated with either HRP-conjugated donkey anti-rabbit IgG from
Amersham (Arlington Heights, IL) or HRP-conjugated rabbit antichicken IgG from Zymed Laboratories at a 1:12,000 dilution in
blocking buffer. Immunoreactivity was detected by using the SuperSignal chemiluminescent substrate from Pierce (Rockford, IL), according to the manufacturer’s instructions.

Additional Reagents
Purified ECM components used as standards were rat collagen I
obtained from Upstate Biotechnology (Lake Placid, NY) and rat
fibronectin from Chemicon International (Temecula, CA). The corresponding antibodies, polyclonal anti-rat collagen I and anti-rat fibronectin from Chemicon International, were used in ELISA. In
preliminary experiments, the former antibody did not cross-react with
fibronectin or laminin, whereas the latter does not cross-react with
collagen I or laminin. The TGF-␤ used for stimulation experiments
was human TGF-␤2 and was a gift from Celtrix Corp. (Santa Clara,
CA). This recombinant cytokine was produced in Chinese hamster
ovary cells, then purified by previously reported techniques (42). A
monoclonal antibody (1.D 11.1) that neutralizes TGF-␤1, -2, and -3
was a generous gift of Genzyme Corp. (Cambridge, MA).

Statistical Analyses
Data were expressed as means ⫾ SEM. For tissue culture data,
unless otherwise noted, differences between two groups were evaluated using a paired t test. A paired test was used because of the cloned
nature of the MC studied. In the case in which results were normalized
to corresponding control values, the data were analyzed by a onesample t test with a hypothesized mean of 100% to compare the test
group with the control. A paired two-sample t test was used to
examine differences between three test groups. In both cases, a
Holm’s test was then applied post hoc to adjust for multiple compar-
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isons (43). For histologic data, the mean sclerosis score was calculated
in the glomeruli of each kidney, and the statistical difference between
the diabetic and control groups was determined using a nonpaired t
test.

Results
CTGF-Induced Changes in ECM Production by MC
We first carried out experiments designed to determine the
effects of exogenous CTGF on the MC production of ECM. To
do this, serum-depleted cells were exposed for 48 h to media
containing 20 ng/ml rhCTGF. For comparison purposes, additional cultures were incubated in media without exogenous
CTGF, but containing either 2 ng/ml TGF-␤, or 20 mM glucose. As anticipated, exogenous TGF-␤ and the high glucose
concentration increased the amount of secreted fibronectin by
23 and 30%, respectively, over that of controls (Figure 1A).
The presence of exogenous CTGF in the media also effectively
stimulated fibronectin secretion (45%). Like fibronectin, the
quantity of secreted collagen type I was also increased by
CTGF (64%), as well as by TGF-␤ (50%) or high glucose
(22%) (Figure 1B).

Renal and MC CTGF Expression:
Regulation by TGF-␤
We next sought to determine whether CTGF mRNA was
expressed by cultured rat MC and then compared the results
with those from whole kidney. Northern analysis demonstrated
a single 2.4-kb CTGF transcript in MC and whole kidney, but
in contrast no detectable message was evident in cultured
kidney fibroblasts (Figure 2). When compared with other tissues, the most abundant expression was in the kidney and was
approximately 20-fold higher than in the brain.
To determine whether TGF-␤ was a regulatory factor in MC
expression of CTGF message, cells were serum-depleted and
exposed to 2 ng/ml TGF-␤ for 24 h, and the mRNA was
probed. Changes in TGF-␤ transcript levels were also monitored. Exogenous TGF-␤ exposure increased the expression of
CTGF mRNA more than fourfold (Figure 3, A and B), whereas
TGF-␤1 mRNA was increased 80% (Figure 3, A and C). To
determine whether CTGF was capable of regulating its own
expression, or that of TGF-␤, MC were also exposed to 20
ng/ml rhCTGF. This treatment failed to alter the level of
TGF-␤ mRNA (Figure 3, A and C), but in contrast, it strongly
autoinduced CTGF message (Figure 3, A and B).
To next demonstrate whether the low CTGF mRNA expression in unstimulated MC was associated with a detectable
production of the corresponding protein, and to determine the
effects of TGF-␤, cells were serum-depleted and then cultured
for an additional 24 h in fresh maintenance medium in the
presence or absence of 2 ng/ml exogenous TGF-␤. The conditioned medium was subsequently heparin-Sepharose-precipitated and analyzed by immunoblotting using two different
anti-CTGF antibodies. Immunoblotting with pIgY3 antibody,
raised against the full-length rhCTGF, demonstrated that under
basal, unstimulated conditions, MC secreted very small
amounts of CTGF (Figure 4A). However, upon exposure to
TGF-␤, the secretion of CTGF protein was markedly stimu-

Figure 1. Effects of exogenous connective tissue growth factor
(CTGF) on mesangial cell (MC) secretion of extracellular matrix
(ECM). Cells grown in a 5 mM glucose medium were serum-depleted
for 48 h, then incubated for an additional 48 h in media containing: (1)
5 mM glucose; (2) 5 mM glucose plus 2 ng/ml transforming growth
factor-␤ (TGF-␤); (3) 5 mM glucose plus 20 ng/ml recombinant
human CTGF (rhCTGF); or (4) 20 mM glucose. The quantities of
fibronectin (A) or collagen type I (B) contained in the media at the end
of incubation were determined by enzyme-linked immunosorbent
assay (ELISA). Bars represent means of six separate cultures in a
representative experiment. Each value shown is the percentage increase over the corresponding control. *P ⬍ 0.05 versus control.

lated. The predominant product detected in these cultures migrated to the same position as the recombinant standard. Immunoblotting of the same samples with pAb839 antibody,
raised against a 15 amino acid sequence unique to CTGF,
confirmed the identity of protein detected (Figure 4B). This
latter antibody, while highly specific for CTGF, is of low
comparative affinity, binding CTGF only when samples are
analyzed under reduced conditions. For that reason, pAb839
antibody was not used in subsequent immunoblotting analyses.
The CTGF protein detected in MC cultures above represents
free molecule present in the media. The existence of a heparinbinding domain within CTGF suggests that a substantial portion of the synthesized and released protein exists bound to
proteoglycans, or to fibronectin, present on the cell surface or
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Figure 2. CTGF gene expression in rat tissues and cultured kidney
cells. Total RNA was extracted from whole organs of rat and from
cultured rat MC and kidney fibroblasts for Northern analysis. Fortymicrogram samples of RNA were loaded per lane and after electrophoresis the membrane was probed for CTGF mRNA. MC, mesangial
cells; BT, brain tissue; HT, heart tissue; KT, kidney tissue; KFC,
kidney fibroblast cells.

in the ECM. To ascertain whether this was the case, and to
determine the time course for appearance of CTGF in the
extracellular environment under unstimulated conditions, MC
cultures were serum-deprived and then fresh maintenance media containing 50 g/ml sodium heparin were added. Conditioned media were collected after defined incubation periods,
the majority of the sample was pooled, and heparin-sulfate was
precipitated. Immunoblotting of the 4-h samples produced faint
CTGF bands at approximately 36 and 39 kD (Figure 5A). The
intensities of these bands increased sharply by 24 h and remained elevated throughout the 72-h incubation period. At 48
and 72 h, when the full-length CTGF bands were intense, a
faint additional band with an electrophoretic mobility of approximately 20 kD could also be seen. As demonstrated previously, in the absence of sodium heparin, the CTGF present in
the media was barely detectable, suggesting that the majority
of CTGF protein produced was bound to the cell and/or substrate. Because immunoblotting is largely a qualitative assay,
individual supernatants were also evaluated by ELISA before
their pooling and precipitation, and the results were expressed
on a per cell basis. This highly quantitative assay demonstrated
a time-dependent increase in CTGF, with approximately 7
ng/106 cells being secreted in a 24-h period (Figure 5B). The
amount of CTGF secreted in the medium during the total 72-h
period was reduced to 20% in the absence of heparin.
We next reexamined the regulation of secreted CTGF by
TGF-␤, this time in the presence of heparin. Accordingly, MC
were serum-deprived as before, then incubated for 48 h in
maintenance media containing 50 g/ml sodium heparin and 2
ng/ml TGF-␤. Immunoblotting of pooled, precipitated media
samples indicated that TGF-␤ markedly increased the secretion
of full-length (36 to 39 kD) CTGF (Figure 6A). However, even
more pronounced was the induction of the molecule(s) appearing at 18 to 20 kD. This smaller moiety corresponds in size to
half of the full-length CTGF molecule. Quantitative analysis
by ELISA of the individual samples, before being pooled and
precipitated for immunoblotting, demonstrated a 2.5-fold enhancement of total secreted CTGF in response to TGF-␤ treatment (Figure 6B).

Figure 3. Regulation of CTGF and TGF-␤ mRNA levels by exogenous TGF-␤ and CTGF. Serum-deprived MC were incubated for 24 h
in the presence of 2 ng/ml TGF-␤ or 20 ng/ml rhCTGF. RNA was
extracted for Northern analyses and probed for TGF-␤1 or CTGF.
Results from a representative experiment are shown (A). Bands for
rRNA (28S and 18S) are shown for comparison. The mRNA bands for
CTGF (B) or TGF-␤ (C) from replicate experiments were quantified
by densitometric analysis, and the results were normalized to the
values of the 28S and 18S ribosomal RNA in the corresponding lanes.
n ⫽ 4. *P ⬍ 0.05 versus control.
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Figure 4. Expression of CTGF protein by cultured MC. Cultures were
serum-depleted and then cultured for an additional 24 h in the presence or absence of 5 ng/ml exogenous TGF-␤. Immunoblotting was
carried out with heparin-Sepharose-treated samples using an antibody
raised against full-length rhCTGF (pIgY3) (A) or a 15 amino acid
sequence specific to CTGF (pAb839) (B). Twenty-five nanograms of
purified rhCTGF was run as a standard. Each sample represents
pooled, conditioned media from three different 100-mm culture
dishes.

MC CTGF Expression: Regulation by
Glucose Concentrations
To determine whether CTGF expression might also be altered by the ambient concentration of glucose, MC cultures
continuously grown in 5 mM glucose were incubated for 14 d
in growth media containing 35 mM glucose. This time was
chosen because our previous studies showed that this period
was required for the full induction of ECM protein production.
As observed previously, MC grown in medium containing 5
mM glucose concentration demonstrated minimal levels of
CTGF message (Figure 7). However, after the long-term exposure to an increased glucose concentration, MC transcripts
for CTGF were markedly upregulated (Figure 7), reaching a
sevenfold level above control, as determined by quantitative
image analysis (data not shown).
To examine the effects of high glucose exposure on the
secretion of CTGF protein, we used serum-deprived cultures,
shortened the exposure time to 48 h, and included sodium
heparin in the medium. This protocol allowed a comparison to
the effects of TGF-␤. Immunoblotting of pooled and precipi-

Figure 5. Secretion of CTGF protein into the medium of MC cultures,
and the effect of heparin. Cultures were serum-depleted, then fresh
maintenance medium containing 50 g/ml sodium heparin was added.
At the indicated periods, the conditioned media were collected and
assayed for CTGF content. Media from three different 100-mm culture dishes were pooled and heparin-Sepharose-concentrated for immunoblotting (A), or tested individually before pooling, by ELISA
(B).

tated media samples indicated that exposure to 20 mM glucose
increased the amount of CTGF secreted (Figure 6A). Interestingly, however, this stimulation appeared to be limited to the
full-length molecule only. Quantification of secreted CTGF
protein by ELISA, before pooling and precipitation, demonstrated a twofold induction by high extracellular glucose levels
(Figure 6B), an increase similar to that induced by TGF-␤,
under the experimental conditions selected. To determine if the
observed increase in CTGF could be due to an osmolar effect,
we repeated these experiments using mannitol. Under these
conditions, there was no induction of CTGF release as mea-
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Figure 7. Effect of high glucose concentration on the MC expression
of CTGF mRNA. Total RNA was extracted from MC grown for 14 d
in a medium containing either 5 or 35 mM glucose. CTGF mRNA
expression was determined by Northern analysis. Corresponding ribosomal RNA are shown for comparison. Shown are samples of
pooled RNA from six different 100-mm culture dishes in a representative experiment.

Figure 6. CTGF protein induction in MC. Cells grown in a medium
containing 5 mM glucose were serum-depleted and then cultured for
an additional 48 h in the presence of 2 ng/ml TGF-␤ or 20 mM
glucose. Control cultures received fresh media containing 5 mM
glucose, without added TGF-␤. All cultures received sodium heparin
(50 g/ml) 48 h before the termination of the experiment. Conditioned
media from three different 100-mm culture dishes were pooled and
heparin-Sepharose-treated for immunoblotting (A), or tested individually before pooling, by ELISA (B). Results from a representative
experiment are displayed. Duplicate lanes (A) represent media from
different pools of media.

sured by ELISA (5 mM glucose, 2.39 ⫾ 0.28 ng/106 cells; 5
mM glucose plus 15 mM mannitol, 1.94 ⫾ 0.32), and no
change in the distribution of CTGF forms secreted as determined by immunoblotting (data not shown).
Because the stimulation of ECM production in MC by high
glucose has been shown to be mediated in large part by TGF-␤
(14,15), we wanted to determine whether this cytokine is also
responsible for the observed effect on CTGF production. Accordingly, MC cultured for 14 d in the presence of either 5 or
20 mM glucose were seeded and grown under the same glucose
conditions for an additional 8-d period. On day 4, the cultures
were serum-deprived and half received 20 g/ml of an antibody that neutralizes TGF-␤1, -2, and -3 activity. Fresh antibody was added daily, and the media was replaced 24 h before
collection. Measurement of CTGF secretion by ELISA demonstrated a stimulatory effect of high glucose (Figure 8), as
observed above. However, neutralization of TGF-␤ activity in
these cultures blocked the induction of CTGF by high glucose.
Although the constitutive secretion of CTGF in the presence of
normal concentrations of glucose also appeared somewhat
reduced by the presence of TGF-␤ antibody, this change was

Figure 8. TGF-␤ blockade of high glucose-induced CTGF production.
MC cultured for 14 d in the presence of either 5 or 20 mM glucose
were seeded and grown under the same glucose conditions for an
additional 8-d period. On day 4, the cultures were serum-deprived and
half of the cultures received 20 g/ml anti-TGF-␤ antibody. Fresh
antibody was added daily, and the media was replaced 24 h before
collection. Media from individual culture wells were tested by ELISA.
n ⫽ 4. *P ⬍ 0.05 versus 5 mM glucose; **P ⬍ 0.05 versus 20 mM
glucose without TGF-␤ antibody.

not statistically significant (P ⫽ 0.09). Also nonsignificant
(P ⫽ 0.075) was the difference in CTGF levels in normal
glucose- and high glucose-treated cells when TGF-␤ was neutralized (Figure 8).

MC CTGF Expression: Regulation by Cyclic
Mechanical Strain
To determine whether cyclic mechanical strain was also a
factor capable of altering MC expression, cells were seeded
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into collagen-coated flexible-bottom plates, then after overnight incubation, they were subjected to either stretch or maintained under static conditions. At the designated periods, the
cells were lysed and total RNA was extracted and probed for
CTGF transcripts. Cyclic stretching induced a rapid and
marked increase in the CTGF message (Figure 9). Quantitative
image analysis of the Northern blot showed that levels of
CTGF mRNA increased more than twofold by 4 h and remained elevated at this level after 8 h of stretching. In separate
experiments, CTGF transcripts were significantly increased
even after 48 h of stretch (not shown).
Experiments were also conducted to investigate whether the
mechanically induced CTGF mRNA levels were accompanied
by an upregulation in the secretion of CTGF protein. To this
end, MC were seeded as described above and the next day
subjected to 24 or 48 h of cyclic stretching. The media was
replaced 24 h before harvest and heparin was added. Quantification of CTGF by ELISA demonstrated that cyclic strain
failed to alter the amount of secreted CTGF (Figure 10A).
Separate experiments showed a similar lack of effect after 4
and 8 h of stretch (data not shown). Additional studies were
then performed in which MC cultures were grown to confluence (4 d), serum-depleted, then subjected to 24 or 48 h of
cyclic stretching in the presence of sodium heparin. Again,
cyclic strain failed to alter the amount of CTGF secreted during
a 24-h period into the media (Figure 10B, bottom). Immunoblotting of heparin-precipitated pooled samples demonstrated
that the molecular species of the secreted CTGF were also
unchanged by stretch (Figure 10B, top).

CTGF Expression in Experimental
Diabetic Nephropathy
To determine whether CTGF is upregulated in early diabetic
nephropathy, studies were carried out on diabetic db/db mice,
and the results were compared to those from age-matched
nondiabetic db/m littermates. At 5 mo of age, approximately
3.5 mo after the onset of diabetes, animals were evaluated for

Figure 9. Effect of cyclic stretching on the MC expression of CTGF
transcripts. Cells cultured overnight on collagen-coated flexible-bottomed dishes were subjected to cyclic stretching or control, static
conditions. At the indicated periods, RNA was extracted and probed
for CTGF message. Each lane represents the results of samples pooled
from 24 different culture wells.

Figure 10. CTGF protein secretion in response to mechanical strain.
(A) MC were cultured under cyclic stretching conditions as described
in Figure 9, except that heparin was added to the medium during the
final 24 h of culture. Samples represent the CTGF analyses by ELISA
in media during the last 24 h of culture. (B) MC were cultured to
confluence, serum-depleted, and then subjected to cyclic stretching in
the presence of heparin. The quantities of CTGF protein contained in
the final 24-h incubation media were analyzed by ELISA (bottom
panel). Immunoblotting results of duplicate, pooled (two cultures/
sample) heparin-Sepharose-treated samples in a representative experiment are shown (top panel). In both bar graphs, n ⫽ 4. Experimental
groups were not significantly different from controls (P ⬎ 0.05).

blood glucose levels, total weight, proteinuria, and mesangial
expansion. At the time of sacrifice, mean blood glucose levels,
as well as body weights, were significantly greater in the db/db
animals (Table 1). Inspection of the renal tissue by light
microscopy demonstrated that the diabetic animals exhibited
noticeable, but minimal, glomerular changes consistent with
early diabetic glomerulosclerosis, i.e., mild mesangial matrix
expansion without apparent tubulointerstitial disease (Figure
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Table 1. Measurement of changes in db/db mice at 5 moa
Characteristic

Control db/m

Diabetic db/db

P Value

Blood glucose
Weight
Proteinuria
Glomerular sclerosis

142 ⫾ 19.0 mg/dl (n ⫽ 8)
29.2 ⫾ 1.00 g (n ⫽ 8)
2.32 ⫾ 1.07 mg/24 h (n ⫽ 10)
0.101 ⫾ 0.048 (n ⫽ 17)

485 ⫾ 58.0 (n ⫽ 6)
43.1 ⫾ 7.30 (n ⫽ 6)
2.78 ⫾ 0.93 (n ⫽ 9)
0.649 ⫾ 0.369 (n ⫽ 6)

⬍0.001
⬍0.001
0.330
0.003

a
Protein excretion was determined in two consecutive 24-h urine collections. The mean value of these two collections was taken as the
degree of proteinuria. A total of 100 to 150 glomeruli per kidney were scored on a scale of 0 to 4 as described in Materials and Methods.
All values are means ⫾ SEM.

11). In addition, the level of proteinuria was not significantly
greater than in controls (Table 1). Semiquantitative analysis
(Table 1) of the glomerular changes demonstrated that the
observed mesangial expansion in the diabetic animals was
indeed consistent but of mild intensity, a value of 0 representing no lesion and a value of 1 representing minimal mesangial
expansion in the majority of glomeruli, without basement
membrane thickening.
Northern analysis of whole kidney RNA indicated that the
CTGF message levels were markedly increased in four out of
five diabetic mice (Figure 12A). These changes were mirrored
by parallel changes in fibronectin transcript levels. Quantification of results yielded a mean 103% increase in CTGF expression, while fibronectin levels were 80% greater than in the
controls (Figure 12B). Analysis of microdissected glomeruli by
quantitative RT-PCR identified a low, but measurable, transcript level of CTGF in the glomeruli of control animals
(Figure 13). However, this level was dramatically increased
(27-fold) in the mice with diabetes. The upregulation of glomerular CTGF mRNA was accompanied by a nearly fivefold

increase in the amount of fibronectin mRNA. These large
differences were not due to dissimilar glomerular size resulting
from diabetic hypertrophy, since the level of GAPDH message
was not significantly increased in diabetic animals compared to
controls (control, 1.39 ⫾ 0.524 ⫻ 10⫺1 attomoles/glomerulus;
diabetic, 2.59 ⫾ 0.307 attomoles/glomerulus; P ⬎ 0.05).

Discussion
This study provides the first evidence demonstrating the
production of CTGF protein by glomerular cells and its role as
a potentially important factor in the pathogenesis of diabetic
glomerulosclerosis. In diabetic glomerulosclerosis, two major,
well-known casual factors are hyperglycemia and glomerular
hypertension. Recent studies have demonstrated that elevated
glucose concentrations and hypertension-induced glomerular
mechanical strain stimulate the overproduction of ECM, a
change that is at least in part mediated through the metabolic
action of TGF-␤ (13,15,16,22). CTGF, a newly described
factor that promotes ECM deposition and fibrosis in the skin,
appears to act downstream of TGF-␤ to induce ECM produc-

Figure 11. Glomerular disease associated with diabetes in db/db mice. Renal cortical sections from control (left) db/m or diabetic (right) db/db
mice at 5 mo of age were stained with periodic acid-Schiff for light microscopy examination. Shown is an example of glomeruli demonstrating
the most severe mesangial expansion observed in the diabetic group.
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Figure 13. Effects of diabetes on the glomerular expression of CTGF
and fibronectin transcript levels in db/db mice. Analyses were carried
out in samples of 50 glomeruli microdissected from each kidney of
five control (db/m) and five diabetic (db/db) mice. After competitive
reverse transcription-PCR, the amount of CTGF mRNA was determined and expressed per glomerulus. *P ⬍ 0.05 versus control.

Figure 12. Induction of CTGF and fibronectin transcripts in whole
kidneys of diabetic db/db mice. At 5 mo of age, total RNA was
extracted from whole kidneys of control nondiabetic (C) or diabetic
(D) mice and probed for CTGF mRNA by Northern analysis (A).
Results of Northern analyses were quantified by densitometric analysis (B). n ⫽ 5. *P ⬍ 0.05 versus control.

tion, but whether TGF-␤ action is obligatory for its overexpression is uncertain. In addition, the role of CTGF in the
development of glomerulosclerosis has not been studied. Here,
we demonstrate that CTGF stimulates cultured MC to produce
the ECM components fibronectin and collagen type I, and that
this induction of ECM formation by CTGF is triggered by
increased glucose concentrations and exogenous TGF-␤. Although findings similar to these have not been previously
reported in glomerular cells, Frazier et al. (29), using qualitative pulse labeling techniques, demonstrated that rhCTGF
treatment increases, as does TGF-␤, the synthesis of ECM
components by a fibroblast cell line. In addition, the relevance
of these findings was demonstrated with the observation that
injection of CTGF into the skin induces the formation of
fibrous tissue (25).
In this study, we demonstrate that CTGF mRNA is expressed in the whole kidney of normal animals, and that its
level is high compared with the heart and brain. This suggests
that endogenously produced cytokine may be involved in normal turnover of renal ECM. However, the low levels of con-

stitutive CTGF mRNA expression demonstrated in cultured
MC suggest that this cell type may have a controlling mechanism for CTGF formation different from that in the cells
forming the bulk of the renal tissue, i.e., tubular epithelial cells.
The low expression of CTGF mRNA observed in MC under
unstimulated conditions is associated with an apparent release
of small quantities of CTGF protein into the culture medium.
The CTGF protein was present as 36 and 38 kD molecular
species. The larger protein is equivalent in size to the fulllength CTGF molecule predicted from gene analysis, whereas
the smaller peptide may represent a differential N-glycosylation in the CTGF N-terminal half. We have observed that in
both insect and mammalian cells pretreated with tunicamycin,
which inhibits the N-glycosylation of glycoproteins, the larger
CTGF band is reduced in its migration to localize with the
smaller moiety (unpublished observation). These molecular
species observed in MC are similar in size to that secreted by
vascular endothelial and fibroblast cells (23,41,44). The small
amounts of CTGF detected in the conditioned medium of MC
cultures are not the result of low levels of its synthesis, but
rather due to the restricted release of the protein into medium.
This was indicated by the ability of sodium-heparin to dramatically increase the levels of CTGF protein measured in the
media. Our results suggest that as much as 80% of the CTGF
synthesized by MC remains cell- or matrix-bound. This finding
is also supported by preliminary receptor studies showing that
exogenous heparin is able to displace iodinated CTGF bound to
the MC surface (J. Nesbitt, personal communication). In a
quantitative assay developed for the current study, it is shown
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that in the presence of heparin, MC secrete approximately 7 ng
of CTGF per 106 cells in each 24-h period.
Given that CTGF stimulates ECM accumulation, we have
examined whether known factors implicated in the development of diabetic glomerulopathy alter CTGF mRNA expression. High extracellular glucose concentrations markedly increase the levels of CTGF mRNA as well as the production of
CTGF protein in MC. In a similar manner, TGF-␤ also upregulates the expression of CTGF mRNA and protein. With
strong upregulation, as occurred in response to TGF-␤, there
was a marked induction of a small molecular weight CTGF
species, which according to its size (approximately 18 kD), is
approximately half of the full-length CTGF molecule. The
structure and biologic role of this CTGF fragment is unknown.
However, its size and properties (recovery from a heparinSepharose column) indicate that it contains both the thrombospondin 1 and the C-terminal modules of CTGF (24). Interestingly, Brigstock and colleagues isolated novel 10-, 16-, and
20-kD heparin-binding molecules from porcine uterine secretions that reacted with CTGF antibody (45). The small molecular species demonstrated in MC following stimulation may
have distinct biologic activities compared with the whole molecule, and is currently under investigation. Because TGF-␤
secretion in MC is stimulated by increased ambient glucose
concentrations (13,15,16,22), the observed induction of CTGF
by high glucose may occur indirectly, mediated by the action
of TGF-␤. Indeed, our neutralization studies demonstrated a
direct role for the cytokine in the process, since incubation with
TGF-␤ antibodies resulted in a complete blockade of CTGF
stimulation.
Cyclic mechanical strain was also examined as a possible
regulatory element in CTGF expression. Our results demonstrate that stretching is a potent stimulus for the upregulation
CTGF mRNA levels. However, in contrast to the effects of
high glucose or TGF-␤, cell stretching does not induce significant changes in the amount or size of the secreted CTGF
protein. The reason for this difference is unknown. It remains
possible, although perhaps unlikely, that our inability to observe increased CTGF protein in response to stretch was due to
inappropriate experimental conditions. The CTGF message
level was strongly increased after 2 h of stretching, and remained elevated at 8 h. However, we found no increase in
CTGF protein after 4, 8, 24, 48, or 72 h of cyclic strain. Similar
results were obtained in cells cultured under both serum and
serum-depleted conditions. A second possible explanation for
these differences is that the response to these two stimuli
follow unique pathways. In the case of cyclic strain, translational control of CTGF may be independent of transcription, as
others have reported for TGF-␤ with certain stimuli (46).
Alternatively, mechanical strain may induce CTGF synthesis
while simultaneously increasing protease activity. This would
result in a greater turnover of the protein without increasing
CTGF accumulation in the medium. We have shown this to be
the case for collagen following cyclic stretch when the glucose
level is not elevated (13).
The rapid induction of CTGF mRNA following stretch suggests that TGF-␤ production and or activity may not be re-
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quired to mediate the initial effects of mechanical strain. Cyclic
strain induces TGF-␤1 synthesis and activation, but this effect
is only evident after 48 to 72 h of mechanical stimulation (21).
Interestingly, we have previously shown that the high collagen
turnover, without medium accumulation, occurring in MC
stretched under physiologic glucose concentrations, is independent of TGF-␤ action (13). However, under conditions of high
glucose, there is an additional enhancement of collagen synthesis, resulting in a marked net collagen accumulation that is
dependent on augmented TGF-␤ activity. Thus, the inability of
stretch to induce collagen accumulation under conditions of
low glucose concentrations, even though TGF-␤ is upregulated, may be related to the insufficient increase in CTGF
protein production. Determination of the role of CTGF in
long-term high glucose-induced and stretch plus high glucoseinduced ECM synthesis and accumulation will require neutralizing antibodies specific for CTGF. Similar blockade studies
will also be necessary to conclude that CTGF is acting downstream of TGF-␤ to induce matrix production. Currently, there
are no such antibodies available.
In addition to the above findings, this study also demonstrates that TGF-␤ and CTGF are able to autoinduce their own
expression in MC. Although this autoinduction has been described previously for TGF-␤ in other cells (47), this is the first
time it has been noted for CTGF. Furthermore, this action
appears to be selective, since exogenous CTGF has no effect
on TGF-␤ transcript levels. These findings suggest that once
stimulated by TGF-␤, CTGF mRNA levels in MC may remain
elevated even in the absence of additional TGF-␤ activity,
resulting in a continued enhancement of ECM synthesis and
deposition. This may help to explain the prevalent inability to
totally block ECM production in MC and in the mesangium by
TGF-␤ neutralization (10 –12).
The studies reported here on the quantitative glomerular
expression of CTGF mRNA in db/db mice strongly suggest
that CTGF action is a factor in the initiation of glomerular
ECM deposition in non-insulin-deficient diabetes. Although
CTGF mRNA is expressed in normal glomeruli, the levels
are dramatically upregulated (28-fold) after a short period of
diabetes and before the onset of overt glomerular disease. In
this study, CTGF mRNA upregulation occurred at a time
when glomerular fibronectin mRNA levels were increased
but glomerular mesangial expansion was minimal and proteinuria insignificant. Compared with glomeruli, the much
lower upregulation of CTGF observed in the whole kidney
suggests that the CTGF is, at least in the early phases of
nephropathy, primarily involved in the induction of the
glomerular alterations. However, in the more advanced
stages of diabetic nephropathy, CTGF may be also an important inducer of tubulointerstitial disease. For example, it
has been shown using an in vitro model of calcium oxalate
nephrolithiasis, that renal tubular epithelial cells respond to
calcium oxalate by upregulating the CTGF gene along with
other genes involved in matrix turnover (48). A similar
response also occurs in the same cells after mechanical
wounding (49). Finally, Ito et al. reported a positive relationship between the number of positive CTGF mRNA-
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expressing interstitial cells and the extent of tubulointerstitial lesions in human biopsies (31).
Findings concurrent with those reported here have been
described in a very recent report which, although limited to
mRNA analyses, shows that CTGF is upregulated in MC
following exposure to high glucose concentrations or TGF-␤
(50). However, in this study, high glucose-induced CTGF
mRNA expression was not fully inhibited by TGF-␤-neutralizing antibodies. In addition, qualitative measurements of
CTGF mRNA demonstrated an increase in glomerular expression in a rat model of insulin-dependent diabetes.
In summary, these studies suggest that in addition to enhanced glomerular TGF-␤ expression, CTGF upregulation is
an important factor in exaggerated deposition of mesangial
matrix. This CTGF upregulation is likely to be maximally
driven by a combination of high glucose concentrations and
cellular mechanical strain via pathways that are both dependent
and independent of a preceding TGF-␤ stimulation. This, together with the study cited above, suggests that glomerular
CTGF is strongly upregulated early in the course of both
insulin-dependent and insulin-independent diabetes inducing
progressive glomerulosclerosis.
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